Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Translation of ischemic preconditioning to the patient: prolyl hydroxylase inhibition and hypoxia inducible factor-1 as novel targets for stroke therapy.

Ratan RR, Siddiq A, Aminova L, Lange PS, Langley B, Ayoub I, Gensert J, Chavez J.

Stroke. 2004 Nov;35(11 Suppl 1):2687-9. Epub 2004 Oct 7. Review.

2.

Prolyl hydroxylase domain inhibitors: a route to HIF activation and neuroprotection.

Harten SK, Ashcroft M, Maxwell PH.

Antioxid Redox Signal. 2010 Apr;12(4):459-80. doi: 10.1089/ars.2009.2870. Review.

PMID:
19737089
3.

HIF-prolyl hydroxylases and cardiovascular diseases.

Sen Banerjee S, Thirunavukkarasu M, Tipu Rishi M, Sanchez JA, Maulik N, Maulik G.

Toxicol Mech Methods. 2012 Jun;22(5):347-58. doi: 10.3109/15376516.2012.673088. Review.

PMID:
22424133
4.

Hypoxia-inducible factor prolyl hydroxylase inhibition: robust new target or another big bust for stroke therapeutics?

Karuppagounder SS, Ratan RR.

J Cereb Blood Flow Metab. 2012 Jul;32(7):1347-61. doi: 10.1038/jcbfm.2012.28. Epub 2012 Mar 14. Review.

5.

The prolyl hydroxylase enzymes that act as oxygen sensors regulating destruction of hypoxia-inducible factor alpha.

Willam C, Nicholls LG, Ratcliffe PJ, Pugh CW, Maxwell PH.

Adv Enzyme Regul. 2004;44:75-92. Review. No abstract available.

PMID:
15581484
6.

Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease.

Semenza GL.

Pediatr Res. 2001 May;49(5):614-7. Review.

PMID:
11328942
7.

Harnessing hypoxic adaptation to prevent, treat, and repair stroke.

Ratan RR, Siddiq A, Smirnova N, Karpisheva K, Haskew-Layton R, McConoughey S, Langley B, Estevez A, Huerta PT, Volpe B, Roy S, Sen CK, Gazaryan I, Cho S, Fink M, LaManna J.

J Mol Med (Berl). 2007 Dec;85(12):1331-8. Epub 2007 Nov 28. Review.

8.

Organ protection by hypoxia and hypoxia-inducible factors.

Bernhardt WM, Warnecke C, Willam C, Tanaka T, Wiesener MS, Eckardt KU.

Methods Enzymol. 2007;435:221-45. Review.

PMID:
17998057
10.

Novel drugs and the response to hypoxia: HIF stabilizers and prolyl hydroxylase.

Nangaku M, Kojima I, Tanaka T, Ohse T, Kato H, Fujita T.

Recent Pat Cardiovasc Drug Discov. 2006 Jun;1(2):129-39. Review.

PMID:
18221080
11.

Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology.

Semenza GL.

Trends Mol Med. 2001 Aug;7(8):345-50. Review.

PMID:
11516994
12.

HIF-1alpha and p53 promote hypoxia-induced delayed neuronal death in models of CNS ischemia.

Halterman MW, Federoff HJ.

Exp Neurol. 1999 Sep;159(1):65-72. Review.

PMID:
10486175
13.

Protein kinases and the hypoxia-inducible factor-1, two switches in angiogenesis.

Mazure NM, Brahimi-Horn MC, Pouysségur J.

Curr Pharm Des. 2003;9(7):531-41. Review.

PMID:
12570801
14.
15.

[Hypoxia and tumors: does HIF-1 transcription factor favor tumor growth or hypoxia?].

Vandenbunder B.

Bull Cancer. 1998 Oct;85(10):843-5. Review. French.

16.

Targeting hypoxia-inducible factor (HIF) as a therapeutic strategy for CNS disorders.

Freeman RS, Barone MC.

Curr Drug Targets CNS Neurol Disord. 2005 Feb;4(1):85-92. Review.

PMID:
15723616
17.

Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases.

Bruegge K, Jelkmann W, Metzen E.

Curr Med Chem. 2007;14(17):1853-62. Review.

PMID:
17627521
18.

Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1.

Semenza GL.

Annu Rev Cell Dev Biol. 1999;15:551-78. Review.

PMID:
10611972
19.

Expression of hypoxia-inducible factor 1: mechanisms and consequences.

Semenza GL.

Biochem Pharmacol. 2000 Jan 1;59(1):47-53. Review.

PMID:
10605934
20.

Regulation of cardiovascular development and physiology by hypoxia-inducible factor 1.

Semenza GL, Agani F, Iyer N, Kotch L, Laughner E, Leung S, Yu A.

Ann N Y Acad Sci. 1999 Jun 30;874:262-8. Review.

PMID:
10415537

Supplemental Content

Support Center